IMVT, ROIV Stocks Slide As Argenx Sjögren’s Trial Failure Hits Drug Class

Data ReadoutnegativeNegative

AI Analysis

Summary

Argenx's Sjögren's trial failure negatively impacts the drug class, causing stock declines in IMVT and ROIV. The failure affects the broader competitive landscape for Sjögren's therapies.

Clinical Trial Data

Primary Endpoint

Not Met

Outcome Details

Trial failure in Sjögren's indication

Importance:7/10

Sentiment:

-0.80

trial_failuresjogrensdrug_class_impactstock_decline

Related Companies

$IMVT $ARGX $ROIV

Read the original article

Published by yahoo_finance on October 8, 2026 5:33 PM

Read Original